Navigation Links
Patients Who Take a Proton-Pump Inhibitor With Medicine to Prevent Blood Clots Are Less Likely to Be Hospitalized for Bleeding Ulcers

ROCKVILLE, Md., March 15 /PRNewswire-USNewswire/ -- Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel – a drug that prevents blood clots – were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the National Heart, Lung, and Blood Institute at the National Institutes of Health.

The study also suggested that combining the drugs did not increase the risk of serious heart problems. Clopidogrel (sold as Plavix, Clopilet, and Ceruvin) is usually prescribed for heart patients to reduce the risk of a heart attack or stroke and can also cause bleeding stomach ulcers. Proton-pump inhibitors, which include pantoprazole (Protonix), omeprazole (Prilosec), lansoprazole (Prevacid),  esomeprazole (Nexium) and rabeprazole (Aciphex), are used to prevent or treat ulcers, acid reflux disease and other stomach acid-related problems.  

Although proton-pump inhibitors are commonly prescribed with clopidogrel to reduce the risk of upper digestive tract bleeding, clinicians worry that this practice may decrease the antiplatelet drug's ability to prevent blood clots. Until now, there has been limited research on the impact of proton-pump inhibitors on either the effectiveness of clopidogrel or on the ability of the proton-pump inhibitors to reduce digestive tract bleeding and which populations of patients may benefit the most from taking the drugs in combination.

"We need to make sure that the medicines we give patients help and don't harm" said AHRQ Director Carolyn M. Clancy, M.D. "This evidence on benefits and risks helps inform the combined use of these two drugs."

The study, published in the March 16 issue of the Annals of Internal Medicine, was based on data from nearly 21,000 patients in the Tennessee Medicaid program between 1999 and 2005. Researchers divided those patients into two groups – those who were prescribed clopidogrel by itself and those who took clopidogrel in combination with a proton-pump inhibitor. The researchers from Vanderbilt University Medical Center in Nashville then determined how many patients in each group had been hospitalized for gastrodoudenal ulcers – raw tissue in the upper part of the small intestine, or duodendum, where it connects to the stomach. The Vanderbilt research team is one of 14 AHRQ-supported Centers for Education & Research on Therapeutics (CERTs).

The researchers found that concurrent use of a proton-pump inhibitor and clopidogrel did not increase patients' risk of heart attack, sudden cardiac death, stroke or other cardiovascular problems. The same was true for patients who had a procedure called percutaneous coronary intervention, also known as angioplasty with stents.

However, the researchers noted that even though they did not find an elevated cardiovascular risk, they cannot rule it out. They noted data from additional studies, including randomized clinical trials, will clarify how combining clopidogrel and proton-pump inhibitors affects heart and vascular health.

The CERTs research program, established in 1999, is administered by AHRQ in consultation with HHS' Food and Drug Administration. Its goal is to serve as a trusted national resource for people seeking to improve health through the best use of medical therapies. The CERTs program includes partnerships of public and private organizations, a national steering committee involving multiple sectors and the CERTs investigators, a coordinating center and 14 research centers.

SOURCE Agency for Healthcare Research & Quality

Back to top
SOURCE Agency for Healthcare Research & Quality
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. ASTRO publishes supplement on protecting cancer patients by reducing radiation doses, side effects
2. Difficulty trusting and reaching out to others may shorten diabetes patients lives
3. Rehab Program Gets Back Pain Patients Back to Work Sooner
4. Strategies increase health-care worker vaccination rates -- protecting patients
5. Newer Blood Thinner Beats Plavix for Bypass Patients
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. SBRT eliminates tumors with promising survival for early-stage inoperable lung cancer patients
8. Pain Relief Often Delayed for Cancer Patients
9. Older Colon Cancer Patients Less Likely to Get Chemo
10. Increased radiation dose does not increase long-term side effects for prostate cancer patients
11. Precision radiation therapy may improve survival rates of some lung cancer patients
Post Your Comments:
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... ... ... is the first health care provider in the region to offer the vBloc® Therapy ... vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients over ... to 45 kg, or a BMI of at least 35 to 39.9 kg with a ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... oncology and hematology continuing medical education (CME), today announced that the first annual ... Hyatt New York. , “The prevention, detection and treatment of gastrointestinal cancers are ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , ... that its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging ... also announced that it has been selected as a 2015 U.S.A. Taste Champion in ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... there are professionals who believe that with innovative technologies and under the right ... patient to get the benefit of a dual-approach to his or her therapeutic ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015  Athletic apparel company Tommie Copper ... pay $1.35 million to settle Federal Trade Commission ... compression clothing would relieve severe and chronic pain ... Tommie Copper,s proposed settlement ... its founder and chairman Thomas Kallish ...
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
(Date:12/1/2015)... Virginia , 1 de diciembre de ... en tecnología para cuchillas de precisión, develó ... programa de identidad de marca. El nuevo ... el diseño y la ingeniería de productos ... la diferencia". ...
Breaking Medicine Technology: